CAMBRIDGE, Mass., Dec. 22, 2016 /PRNewswire/ — Neurable, a developer of brain-computer interface (BCI) technology based on breakthrough neuroscience, has raised a $2M seed round to bring its software platform to market. Brian Shinled the round through Accomplice’s Boston Syndicate with participation from Point Judith Capital, Loup Ventures, the Kraft Group, NXT Ventures, and prominent angel investors. ...
Post
New study explains how low-dose aspirin may prevent cancer
Cancer is a leading cause of morbidity and death worldwide, and its prevalence is predicted to increase in the next few years. Cancer prevention strategies include making healthy lifestyle choices and getting tested if at risk. New research suggests that a small dose of aspirin may help prevent the formation of cancer cells and explains...
Post
Could a narcolepsy drug help combat food addiction?
A prescription drug used to treat narcolepsy and other sleep disorders has the potential to help people whose obesity is driven by food addiction. This is the conclusion of a new study published in the journal Personality and Individual Differences. Researchers suggest that a drug used to treat narcolepsy may also help tackle obesity driven...
Post
Nanodiscs target tumors in potential cancer vaccine
Nanodiscs may be used in a vaccine against some types of cancer, with a new study finding the technology effective in killing and preventing recurrence of tumors(Credit:lightsource/Depositphotos) Colon and melanoma cancers could soon be treated with a simple vaccine, if research from the University of Michigan lives up to its early promise. Using synthetic nanodiscs, scientists...
Post
Is this why women are more likely to get arthritis? Scientists have identified a ‘master switch’ gene that causes their immune system to attack itself
Some 8 out of 10 cases of autoimmune diseases are believed to affect women Researchers have pinpointed the key gene that controls their immune system Called VGLL3 – it regulates cells and could pave a way for a drug that targets it A ‘master switch’ that makes women more prone to arthritis has been...
Post
Bone Marrow Mesenchymal Stem Cells Spontaneously Make Cartilage After Blockage of VEGF Signaling
Bone marrow-derived mesenchymal stem cells (MSCs) can be induced to make cartilage by incubating the cells with particular growth factors. Unfortunately, batches of MSCs show respectable variability from patient-to-patient. Therefore the growth factor-dependent method suffers from poor efficacy, limited reproducibility from batch-to-batch, and the cell types that are induced are not always terribly stable. Finding a better...
Post
Scientists discover boost for men who get no help from Viagra… in new daily incontinence pill
Doctors say Mirabegron could provide an alternative for one in three men Drug works by relaxing muscles in the penis, allowing more blood to flow to it Erectile dysfunction is a common problem, often effecting men in middle age Can occur as result of vascular issues, such as high blood pressure and diabetes A...
Post
Controlling CRISPR: Researchers May Have Found An “Off-Switch” for Gene-Editing
IN BRIEF Researchers have uncovered two distinct anti-CRISPR proteins — AcrIIA2 and AcrIIA4 — that worked to inhibit the ability of SpyCas9 to target specific genomes in bacteria. The discovery could lead to an “off switch” for CRISPR that would give scientists greater control over the gene editing tool when using it in human subjects....
Post
Could new bone-forming growth factor reverse osteoporosis?
Scientists at the Children’s Medical Center Research Institute at UT Southwestern in Dallas, TX, have uncovered a new bone-forming growth factor that may reverse the bone loss associated with osteoporosis. They say that this discovery has implications for regenerative medicine. Osteolectin has been shown to promote bone growth in postmenopausal mice. Osteoporosis develops over several...
Post
Promising Study Results for Diabetic Kidney Disease Seen with Mesoblast’s Cell Therapy
Mesoblast recently announced positive results from the placebo-controlled Phase 2 trial of its cell therapy MPC-300-IV for diabetic kidney disease patients. All results can be found in the paper “Allogeneic Mesenchymal Precursor Cells (MPC) in Diabetic Nephropathy: A Randomized, Placebo Controlled, Dose Escalation Study,” published in the journal EBioMedicine. The clinical trial, conducted by researchers at the University...